Categories
PREVIOUS TRIALS TRIAL

XXXX XXXXXXX for Pediatric Psoriasis

XXXX XXXXXXX for Pediatric Psoriasis

Trial – Amgen | PPD

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXXXX (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.

Categories
PREVIOUS TRIALS TRIAL

Suffering from Atopic Dermatitis?

Suffering from Atopic Dermatitis?

Trial – Syneos Health/Eli Lilly

Eli Lilly and Company are conducting a study on an investigational drug called XXXXXXXXX as a possible treatment for moderate-to-severe atopic dermatitis (AD). This study will also include 2 vaccines commonly used in adults with AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap).

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # J2T-MC-KGAK/DRM06-AD18

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.

Categories
PREVIOUS TRIALS

Hidradenitis Suppurativa Trial

Hidradenitis Suppurativa Trial

Phase III Clinical Trial – Novartis

A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

To participate in your local study, please contact  (949) 707-5734 or fill out the form below.

CAIN457M2302

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.